Chengdu Easton Biopharmaceuticals Co., Ltd.SSE: 688513

(688513)"Chengdu Easton Biopharmaceuticals Co., Ltd."Announcement on Voluntary Disclosure of Obtaining Drug Registration Certificate for Vitamin K1 Injection

· Issued by Chengdu Easton Biopharmaceuticals Co., Ltd. via Shanghai Stock Exchange

Filed with SSE · Stock code 688513 · · 2 pages · Chinese

Summary by 6ix AI

The drug is classified as a chemical drug and is approved for use in preventing and treating vitamin K deficiency in infants.

Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries

On 6ix: 6ix.com/news/688513chengdu-easton-biopharmaceuticals-co-ltdannouncement-on-voluntary-disclosure-of-obtaining-drug-registration-certificate-for-vitamin-k1-injection

Release

Announcement on Voluntary Disclosure of Obtaining Drug Registration Certificate for Vitamin K1 Injection

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:

Chengdu Easton Biopharmaceuticals Co., Ltd. on 6ix

Story so far

Earlier from Chengdu Easton Biopharmaceuticals

Later from Chengdu Easton Biopharmaceuticals

All Chengdu Easton Biopharmaceuticals news releases